The paper demonstrates that no two manufacturing processes for PPS create a chemically similar product and that different preparations elicit different responses with respect to use of a PK activation assay and Factor XII activation assay, with the results showing bene's product being significantly less potent than the other PPS products tested. This may be ideal from a safety perspective since it appears these other products may pose a greater safety issue due to potential clotting risks.
research reports and media, page-3861
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.0¢ |
Change
0.005(2.56%) |
Mkt cap ! $70.04M | |||
| Open | High | Low | Value | Volume |
| 20.5¢ | 21.0¢ | 20.0¢ | $93.93K | 463.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 220320 | 19.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.5¢ | 54053 | 7 |
View Market Depth
| Last trade - 11.33am 10/10/2024 (20 minute delay) ? |
| PAR (ASX) Chart |